继发性甲状旁腺机能亢进患者在血透基础上联用骨化三醇后ALP、iPTH指标变化探究

目的:探讨继发性甲状旁腺机能亢进患者在血透基础上联用骨化三醇后全段甲状旁腺激素(intact parathyroid hormone,iPTH)、碱性磷酸酶(alkalinephosphatase,ALP)指标变化情况.方法:选取我院2019年1月到2019年12月共收治的维持血液性透析继发性甲旁亢患者80例,随机分为...

ALP and IPTH Index Levels in Patients with Secondary Hyperthyroidism Combined with Calcitriol Based on Hemodialysis

ABSTRACT Objective: To investigate the changes of ALP and iPTH indexes in patients with secondary hyperthyroidism combined with calcitriol on the basis of hemodialysis. Methods: A total of 80 patients with secondary hyperthyroidism who maintained hemodialysis who were admitted to our hospital from January 2019 to December 2019 were selected as the research object. The patients were randomly divided into an observation group and a control group. Each group of 40 patients was given The patients in the control group were given conventional treatment, and the patients in the observation group were treated with calcitriol on the basis of hemodialysis, and the treatment effects, changes in blood-related indicators, and the incidence of adverse reactions were compared between the two groups. Results: The total effective rate of treatment in the control group was 72.5 %, and the total effective rate in the observation group was 90.0 %. The observation group was significantly better than the control group (P<0.05). The iPTH, ALP, P, Ca of the two groups of patients before treatment There was no significant difference (P>0.05). After treatment, the blood parameters related to iPTH, ALP, P, and Ca in the observation group were significantly better than those in the control group (P<0.05). Comparing the adverse reactions between the two groups, the incidence of adverse reactions after treatment was found in the patients There was no significant difference (P>0.05). Conclusion: Combined use of calcitriol on the basis of hemodialysis in patients with secondary hyperthyroidism can improve the patient''s treatment effect and improve the patient''s related blood indicators, and the occurrence of adverse reactions is not significantly different from conventional treatment. It is safe and reliable, and is worthy of clinical Application promotion.